Nearly 3 in 10 Device Therapies for Parkinson's Are Stopped

Nearly 3 in 10 Device Therapies for Parkinson's Are Stopped

TOPLINEAmong patients with Parkinson's disease (PD), nearly 30% of device-aided therapies (DATs) were discontinued, mostly because of therapy- and/or device-related adverse events or patient decision. Discontinuation was much less frequent with deep brain stimulation (DBS) than with infusion therapies. Institutional caregiving, higher ON-state disease stage, and longer daily OFF time were independently linked to discontinuation.METHODOLOGYUsing data from a Spanish registry, researchers conducted a prospective, multicentre, real-world study to assess whether discontinuation rates and time to treatment optimisation varied across DATs for PD and to identify factors associated with treatment discontinuation.They included 565 patients with PD (mean age, 67.1 years; 58.3% men) who received a total of 591 DATs between January 2024 and May 2026.The DATs were DBS (n = 97), continuous subcutaneous apomorphine infusion (CSAI; n = 132), subcutaneous foslevodopa/foscarbidopa (fLD/fCD; n = 291), levodopa-carbidopa intestinal gel (LCIG; n = 14), and levodopa-entacapone-carbidopa intestinal gel (LECIG; n = 57).The time to optimisation was measured as the number of days from treatment start until the treating neurologist determined that the patient had achieved optimal symptom control.TAKEAWAYOverall, 28.8% of DATs were discontinued. Discontinuation rates varied significantly across therapies: 4.1% with DBS, 34.1% with CSAI, 34.7% with fLD/fCD, 28.6% with LCIG, and 28.1% with LECIG (P < .0001). After excluding DBS, the rates did not differ among the infusion therapies.Therapy- and/or device-related adverse events (38.2%), patient decision (25.3%), death (10.0%), and lack of efficacy (10.0%) were the most common reasons for discontinuing the therapies.Across all therapies, the mean time to optimisation was 61.6 days. It was shortest with LECIG (19.6 days) and longest with DBS (115.2 days; P < .0001 across therapies).After adjustment, treatment discontinuation was independently associated with having institutional staff as the principal caregiver (adjusted hazard ratio [HR], 5.162), higher ON-state disease stage (adjusted HR, 1.814), or longer daily OFF time (adjusted HR, 1.093; P < .05 for all).IN PRACTICE"[The study] findings emphasize that DAT persistence depends not only on the selected therapy but also on disease severity, functional status, patient preference, and the caregiving environment," the authors wrote.SOURCEThis study was led by Diego Santos García, Department of Neurology, Hospital Universitario de A Coruña, Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain. It was published online on November 06, 2026, in the Journal of Neurology.LIMITATIONSTreatment allocation was not randomised, and patient selection differed across therapies. Progressive recruitment led to variable exposure times and follow-up durations among participants. Treatment optimisation and reasons for stopping therapy partly depended on individual clinical judgement.DISCLOSURESThe Fundación Degén supported the Spanish Registry. Several authors declared receiving honoraria for educational presentations and advice services and/or honoraria and grants for lecturing and advisory services from different pharmaceutical companies.This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Original Source

Read the full article at Medscape →

KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.